Trastuzumab deruxtecan
- Generic Name
- Trastuzumab deruxtecan
- Brand Names
- Enhertu
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1826843-81-5
- Unique Ingredient Identifier
- 5384HK7574
- Background
Trastuzumab deruxtecan is a HER-2 directed antibody attached to a topoisomerase inhibitor that is approved for use in certain types of metastatic, unresectable breast cancer. It is classified as an antibody-drug conjugate. The cleavable peptide linker used to bind the antibody and drug in this product distinguishes it from other members of its class. Trastuz...
- Indication
In the US, trastuzumab deruxtecan is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy. It...
- Associated Conditions
- Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Adenocarcinoma, Metastatic Breast Cancer, Metastatic Breast Cancer With HER2 Positive, Unresectable Breast Cancer, Locally advanced HER2-positive Adenocarcinomas of the Gastroesophageal Junction, Locally advanced HER2-positive Gastric Adenocarcinoma, Metastatic HER2 Mutant Non-small Cell Lung Cancer, Metastatic HER2-low Breast Cancer, Metastatic HER2-positive Adenocarcinomas of the Gastroesophageal Junction, Metastatic HER2-positive Gastric Adenocarcinoma, Unresectable HER2 Mutant Non-small Cell Lung Cancer, Unresectable HER2-low Breast Cancer, Unresectable HER2/Neu-positive Breast Cancer
- Associated Therapies
- -
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
- Conditions
- Interventions
- First Posted Date
- 2021-01-12
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 490
- Registration Number
- NCT04704934
- Locations
- 🇦🇷
Instituto Medico Especializado Alexander Fleming, Colegiales, Caba, Argentina
🇦🇷IONC Instituto Oncologico de Cordoba - Fundacion Richardet Longo, Nueva Cordoba, Cordoba, Argentina
🇦🇷Exelsus, San Miguel De Tucumán, Tucumán, Argentina
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
- Conditions
- Advanced Malignant Solid NeoplasmAdvanced Colon CarcinomaAdvanced Gastroesophageal Junction AdenocarcinomaClinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8Stage III Major Salivary Gland Cancer AJCC v8Stage III Uterine Corpus Cancer AJCC v8Stage IV Colorectal Cancer AJCC v8Unresectable Colorectal CarcinomaAdvanced Gastric CarcinomaAnatomic Stage IV Breast Cancer AJCC v8
- Interventions
- First Posted Date
- 2021-01-12
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 51
- Registration Number
- NCT04704661
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States
🇺🇸Los Angeles General Medical Center, Los Angeles, California, United States
Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2020-11-25
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 152
- Registration Number
- NCT04644237
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇨🇦University Health Network, Toronto, Canada
🇦🇺Princess Alexandra Hospital, Woolloongabba, Australia
A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations
- Conditions
- Interventions
- First Posted Date
- 2020-11-20
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 102
- Registration Number
- NCT04639219
- Locations
- 🇪🇸
Research Site, Sevilla, Spain
A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)
- Conditions
- Interventions
- First Posted Date
- 2020-11-09
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 1600
- Registration Number
- NCT04622319
- Locations
- 🇺🇸
MedStar Franklin Square Cancer Center at Loch Raven Campus, Baltimore, Maryland, United States
🇺🇸Houston Methodist Sugarland, Sugar Land, Texas, United States
🇺🇸MultiCare Cancer Center Puyallup, Puyallup, Washington, United States
Trastuzumab Deruxtecan for the Treatment of HER2+ Newly Diagnosed or Recurrent Osteosarcoma
- Conditions
- Interventions
- First Posted Date
- 2020-11-05
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 27
- Registration Number
- NCT04616560
- Locations
- 🇺🇸
Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
🇺🇸Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-09-21
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 138
- Registration Number
- NCT04556773
- Locations
- 🇨🇳
Research Site, Taoyuan, Taiwan
Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-09-17
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 88
- Registration Number
- NCT04553770
- Locations
- 🇺🇸
St. Joseph Heritage Healthcare, Fullerton, California, United States
🇺🇸Cancer Blood and Specialty Clinic, Los Alamitos, California, United States
🇺🇸UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-09-07
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT04539938
- Locations
- 🇺🇸
UCLA Department of Medicine - Hematology & Oncology, Los Angeles, California, United States
🇺🇸University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-09-04
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 245
- Registration Number
- NCT04538742
- Locations
- 🇬🇧
Research Site, Buckhurst Hill, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.